Literature DB >> 22143347

Synthesis of heparin oligosaccharides and their interaction with eosinophil-derived neurotoxin.

Shang-Cheng Hung1, Xin-An Lu, Jinq-Chyi Lee, Margaret Dah-Tsyr Chang, Shun-lung Fang, Tan-chi Fan, Medel Manuel L Zulueta, Yong-Qing Zhong.   

Abstract

A convenient route for the synthesis of heparin oligosaccharides involving regioselective protection of D-glucosamine and a concise preparation of rare L-ido sugars from diacetone α-D-glucose is described. Stereoselective coupling of a D-glucosamine-derived trichloroacetimidate with a 1,6-anhydro-β-L-idopyranosyl 4-alcohol gave the desired α-linked disaccharide, which was used as repeating unit for dual chain elongation and termination. Stepwise assembly from the reducing to the non-reducing end with a D-glucosamine-derived monosaccharide as starting unit furnished the oligosaccharide skeletons having different chain lengths. A series of functional group transformations afforded the expected heparin oligosaccharides with 3, 5 and 7 sugar units. Interaction of these oligosaccharides with eosinophil-derived neurotoxin (EDN), a cationic ribonuclease and a mediator produced by human eosinophils, was further investigated. The results revealed that at 5 μg mL(-1), the heptasaccharide has sufficiently strong interference to block EDN binding to Beas-2B cells. The tri- and pentasaccharides have moderate inhibitory properties at 50 μg mL(-1) concentration, but no inhibition has been observed at 10 μg mL(-1). The IC(50) values of the tri-, penta- and heptasaccharides are 69.4, 47.2 and 0.225 μg mL(-1), respectively.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22143347     DOI: 10.1039/c1ob06415k

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  8 in total

1.  Engineer P. multocida Heparosan Synthase 2 (PmHS2) for Size-Controlled Synthesis of Longer Heparosan Oligosaccharides.

Authors:  Lan Na; Hai Yu; John B McArthur; Tamashree Ghosh; Thomas Asbell; Xi Chen
Journal:  ACS Catal       Date:  2020-05-11       Impact factor: 13.084

2.  Regioselective monodeprotection of peracetylated carbohydrates.

Authors:  Marco Filice; Jose M Guisan; Marco Terreni; Jose M Palomo
Journal:  Nat Protoc       Date:  2012-09-06       Impact factor: 13.491

3.  Tetrasaccharide iteration synthesis of a heparin-like dodecasaccharide and radiolabelling for in vivo tissue distribution studies.

Authors:  Steen U Hansen; Gavin J Miller; Claire Cole; Graham Rushton; Egle Avizienyte; Gordon C Jayson; John M Gardiner
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

4.  Making the longest sugars: a chemical synthesis of heparin-related [4] n oligosaccharides from 16-mer to 40-mer.

Authors:  Steen U Hansen; Gavin J Miller; Matthew J Cliff; Gordon C Jayson; John M Gardiner
Journal:  Chem Sci       Date:  2015-07-24       Impact factor: 9.825

5.  Synthesis of disaccharides containing 6-deoxy-α-L-talose as potential heparan sulfate mimetics.

Authors:  Jon K Fairweather; Ligong Liu; Tomislav Karoli; Vito Ferro
Journal:  Molecules       Date:  2012-08-15       Impact factor: 4.411

6.  Chemical and chemoenzymatic routes to bridged homoarabinofuranosylpyrimidines: Bicyclic AZT analogues.

Authors:  Sandeep Kumar; Jyotirmoy Maity; Banty Kumar; Sumit Kumar; Ashok K Prasad
Journal:  Beilstein J Org Chem       Date:  2022-01-11       Impact factor: 2.883

7.  In silico prediction and in vitro characterization of multifunctional human RNase3.

Authors:  Pei-Chun Lien; Ping-Hsueh Kuo; Chien-Jung Chen; Hsiu-Hui Chang; Shun-lung Fang; Wei-Shuo Wu; Yiu-Kay Lai; Tun-Wen Pai; Margaret Dah-Tsyr Chang
Journal:  Biomed Res Int       Date:  2013-01-17       Impact factor: 3.411

8.  Basic amino acid residues of human eosinophil derived neurotoxin essential for glycosaminoglycan binding.

Authors:  Ta-Jen Hung; Wei-Tang Chang; Noboru Tomiya; Yuan-Chuan Lee; Hao-Teng Chang; Chien-Jung Chen; Ping-Hsueh Kuo; Tan-chi Fan; Margaret Dah-Tsyr Chang
Journal:  Int J Mol Sci       Date:  2013-09-16       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.